Oncology-New York最新文献

{"title":"Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.","authors":"Viola Maria Popov, Diana Grasu, Horia Bumbea, Camelia Dobrea, Bogdan Mastalier, Ion Dumitru, Mirela Voicu, Mihaela Andreescu","doi":"10.46883/2026.25921072","DOIUrl":"10.46883/2026.25921072","url":null,"abstract":"<p><p>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive lymphoma with a poor prognosis. The human T-lymphotropic virus 1 (HTLV-1) is associated with immunodeficiency and increased extranodal involvement in patients with diffuse large B-cell lymphoma (DLBCL). We report on a 47-year-old woman with spastic paraparesis and hepatitis B who was diagnosed with the acute form of ATLL. The clinical picture reveals peripheral generalized lymphadenopathy and splenomegaly. Findings on a hematologic exam indicated leukocytosis with lymphocytosis. A bone marrow biopsy/aspiration confirmed 50% T-cell lymphoid infiltration. Biochemistry results revealed hypercalcemia and a high lactate dehydrogenase value. Results of a CT scan indicated abdominal and thoracic adenopathy as well as moderate splenomegaly. A supraclavicular lymph node biopsy established a DLBCL diagnosis. The final diagnosis was composite lymphoma, DLBCL, and ATLL. The CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate [Oncovin], and prednisone) regimen was chosen due to the patient's ECOG performance status. Multiple infectious complications were diagnosed during chemotherapy-induced secondary aplasia. A complete remission, confirmed via PET-CT imaging, was obtained. After 1 month, a skin tumor on the upper right thigh was discovered and biopsied, and the histopathological exam and immunochemistry findings indicated Epstein-Barr virus-DLBCL lymphoma. The association of 2 aggressive lymphomas in a single HTLV-1 carrier is a rare report, and the evolution was severe, complicated by opportunistic infections, and unfavorable.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 3","pages":"162-164"},"PeriodicalIF":2.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Quality Audit Standardizing Esophageal Contouring in Postmastectomy Radiotherapy.","authors":"Manjinder Singh Sidhu, Deepak Abrol, Mohan Lal, Sumeet Aggarwal, Prachi Kalra, Rajesh Natte, Sushil Beriwal","doi":"10.46883/2026.25921068","DOIUrl":"10.46883/2026.25921068","url":null,"abstract":"<p><strong>Background: </strong>Postmastectomy radiotherapy (PMRT) delivered with volumetric modulated arc therapy (VMAT) often results in higher esophageal doses than 3D techniques. Recent dose-toxicity studies recommend limiting the esophageal mean dose (D mean ) to less than 11 Gy, based on contours drawn from the cricoid to the carina. In contrast, our network's auto-segmentation delineates the entire esophagus, potentially underestimating dose to clinically relevant upper esophageal segments. This audit evaluated current dose-reporting practices and their implications for toxicity.</p><p><strong>Methods: </strong>A multicenter retrospective audit of 43 consecutive PMRT cases (March 10 to May 5, 2025) across 8 centers was performed. All sites recontoured the esophagus using the cricoid-to-carina definition and submitted paired dosimetric values. One center reported grade 2 esophagitis rates in a separate clinical cohort before and after implementing the standardized contouring approach.</p><p><strong>Results: </strong>Standardized contouring increased the networkwide mean esophageal dose from 6.1 Gy to 11.7 Gy. The median D mean increased from 5.7 Gy to 9.6 Gy ( P  < .001). Sixteen of 42 evaluable patients (38.1%) exceeded the 11-Gy benchmark. In the separate cohort, grade 2 esophagitis decreased from 6 of 7 pre-standard operating procedure (SOP) to 0 of 7 post SOP ( P  = .004).</p><p><strong>Conclusion: </strong>Standardizing esophageal contouring improves dose accuracy and is associated with reduced symptomatic esophagitis, supporting routine use of cricoid-to-carina contours to enhance toxicity risk assessment in PMRT.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 2","pages":"10-14"},"PeriodicalIF":2.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Influencing Factors of Quality of Life During Maintenance Phase in Patients With Breast Cancer-Related Lymphedema.","authors":"Zebing Luo, Manjia Xu, Shuxian Yu, Weijie Gao, Xinxian Lv, Chujun Chen","doi":"10.46883/2026.25921064","DOIUrl":"10.46883/2026.25921064","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to understand the degree of influence of the severity of lymphedema on quality of life (QOL) in patients with breast cancer-related lymphedema (BCRL) during the maintenance phase, and to understand the influencing factors of QOL to identify targeted interventions to improve QOL for patients with BCRL.</p><p><strong>Methods: </strong>This cross-sectional study was conducted among patients with BCRL who underwent complete decongestive therapy during the intensive phase of BCRL treatment from January 2022 to December 2024 at the lymphedema outpatient clinic. General information and the specific QOL scale for upper limb lymphedema were collected. One-way ANOVA and multiple linear regression were used in IBM SPSS (Statistical Package for Social Sciences) version 25to analyze factors affecting QOL.</p><p><strong>Results: </strong>This study included a total of 153 patients, with an overall QOL score of 48.52 plus or minus 12.112. Multivariate linear analysis indicated that the time from discovery of lymphedema to treatment and the severity of lymphedema affected the QOL of patients with BCRL during the maintenance phase.</p><p><strong>Conclusion: </strong>Long-term monitoring and timely treatment are necessary for patients with BCRL. Before the start of the maintenance phase, it is important for lymphedema therapists to treat BCRL disease as soon as possible.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 2","pages":"115-122"},"PeriodicalIF":2.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When the World Stopped: A Lesson in Strength and Second Chances.","authors":"Yan Leyfam","doi":"10.46883/2026.25921069","DOIUrl":"10.46883/2026.25921069","url":null,"abstract":"<p><p>Yan Leyfman, MD, reflected on resilience and hope in the face of cancer, recounting a 37-year-old diagnosed with stage IV colorectal cancer followed by HIV.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 2","pages":"137"},"PeriodicalIF":2.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study.","authors":"Shiny Chih-Hsuan Wu, Yao-Yu Wu, Chi-Ting Liau, Chih-Hsiang Chang, Shih-Chiang Huang, Hsin-Nung Shih, Chun-Chieh Chen","doi":"10.46883/2026.25921066","DOIUrl":"10.46883/2026.25921066","url":null,"abstract":"<p><strong>Background: </strong>Soft tissue sarcomas (STS) are rare but aggressive tumors. Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.</p><p><strong>Methods: </strong>This retrospective study evaluated the effectiveness of single-agent doxorubicin in resectable grade 2 and 3 STS, with a focus on oncologic outcomes. Adults with biopsy-confirmed STS of the extremities or trunk, treated at a tertiary center in Taiwan between January 2004 and March 2020, were included. Primary outcomes were distant metastasis-free survival (DMFS) and overall survival (OS).</p><p><strong>Results: </strong>The study enrolled 62 patients in either the single-agent doxorubicin adjuvant chemotherapy group (n = 8) or the observation-only group (n = 54). The mean age was 45.4 years in the adjuvant chemotherapy group and 58.2 years in the observation-only group. The 3-year OS was 100% in the chemotherapy group and 60% in the observation group (log-rank P = .064). The 3-year DMFS rate was 75% in the chemotherapy group and 45% in the observation group (log-rank P = .078).</p><p><strong>Conclusion: </strong>In resectable, high-grade STS of 8 cm or more, single-agent doxorubicin as adjuvant chemotherapy showed a trend toward improved OS and DMFS compared with observation alone; however, statistical significance was not reached.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 2","pages":"106-114"},"PeriodicalIF":2.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer.","authors":"Dapeng Wu, Juanjuan Cui, Wenjing Zhum, Tao Qin, Hanlin Xu","doi":"10.46883/2026.25921065","DOIUrl":"10.46883/2026.25921065","url":null,"abstract":"<p><strong>Objective: </strong>Immunotherapy combined with chemotherapy is a standard treatment for advanced non-small cell lung cancer (NSCLC). However, the comparative efficacy and safety of cost-efficient modified PD-1 inhibitors remain incompletely characterized. This study aimed to determine the optimal choice for the 3 most commonly used modified PD-1 inhibitors-tislelizumab, sintilimab, and camrelizumab-combined with chemotherapy in locally advanced or metastatic NSCLC.</p><p><strong>Materials and methods: </strong>We conducted a retrospective study of patients with NSCLC who received chemotherapy plus 1 of the modified PD-1 inhibitors. The primary objective was to compare survival and therapeutic responses across groups. The secondary objective was to analyze adverse events in each group.</p><p><strong>Results: </strong>No significant differences were observed in median progression-free survival (PFS) or overall survival across the 3 groups. However, PD-L1-positive patients (tumor proportion score ≥ 1%) demonstrated significantly prolonged PFS with tislelizumab ( P =  .038) and sintilimab ( P =  .031) vs camrelizumab. The incidence of immune-related adverse events did not differ statistically across treatments.</p><p><strong>Conclusion: </strong>Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1-positive subgroups, suggesting biomarker-driven therapeutic selection. These findings underscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical insights for personalized treatment strategies.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 2","pages":"123-133"},"PeriodicalIF":2.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?","authors":"Taha Kassim Dohadwala, Jenna Ghazal, Soumiya Nadar, Riya Vaishnav, Ishan Paduvagere, Viviana Cortiana, Chandler H Park, Yan Leyfman","doi":"10.46883/2026.25921059","DOIUrl":"10.46883/2026.25921059","url":null,"abstract":"<p><p>Multiple myeloma, the second most common hematologic malignancy, accounts for approximately 10% of all blood cancers. Therapeutic advances have transformed multiple myeloma from a uniformly fatal disease into a chronic, manageable condition. Autologous stem cell transplantation (ASCT) remains a cornerstone of frontline treatment, demonstrating superiority in progression-free survival (PFS) and minimal residual disease (MRD) negativity compared with chemotherapy alone or modern induction regimens without transplant. International guidelines continue to recommend ASCT as the standard of care for eligible patients. Maintenance therapy post ASCT further improves PFS and overall survival, although it carries a modestly increased risk of secondary malignancies. Meanwhile, novel immunotherapies, including chimeric antigen receptor T cells and bispecific antibodies, are reshaping treatment strategies, showing strong efficacy in relapsed/refractory multiple myeloma. Ongoing trials are evaluating their role in frontline settings, with the potential to complement or replace ASCT. The future of multiple myeloma management hinges on precision medicine, using MRD assessment, genomic profiling, and patient-specific risk stratification to guide therapy. As these personalized approaches are integrated alongside established therapies, the goal of achieving long-term remission and potentially a cure becomes increasingly attainable.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 1","pages":"34-42"},"PeriodicalIF":2.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Immunotherapy for Breast Cancer.","authors":"Sarah Poland, Matheus de Oliveira Andrade Md, Rita Nanda","doi":"10.46883/2026.25921061","DOIUrl":"10.46883/2026.25921061","url":null,"abstract":"<p><p>Immunotherapy has transformed the treatment of a variety of malignancies, including breast cancer. Given the unmet clinical need, immunotherapy was first studied in advanced-stage, triple-negative breast cancer (TNBC). The anti-PD-1 agent pembrolizumab plus chemotherapy is approved for both advanced and early TNBC, and data from randomized phase 3 trials in high-risk, early-stage, hormone receptor-positive breast cancer have demonstrated promising efficacy. Ongoing trials aim to identify the most appropriate patients for treatment, amount and timing of immunotherapy needed for optimal outcomes, and ideal combination of therapies to maximize survival while minimizing toxicity. The future of immunotherapy in breast cancer will continue to evolve with the advent of novel immunologic agents. In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 1","pages":"8-15"},"PeriodicalIF":2.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13352594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Words Fall Short: A Lesson in Silence and Compassion.","authors":"Yan Leyfman","doi":"10.46883/2026.25921062","DOIUrl":"10.46883/2026.25921062","url":null,"abstract":"<p><p>What is Humanities in Medicine? ONCOLOGY dives beyond clinical metrics of survival rates and molecular pathways and explores the narrative medicine of diagnosis, the ethical complexities of end-of-life care, and the psychological impact of chronic illness on both patients and practitioners. This section aims to enhance provider empathy, mitigate burnout, and center the patient's lived experience within the rigorous framework of medical science.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 1","pages":"43"},"PeriodicalIF":2.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote Exercise Program for Patients With Metastatic Renal Cell Carcinoma Undergoing Immunotherapy: An EXIO Case Series Report.","authors":"Paulo Gustavo Bergerot, Cristiane D Bergerot, Kathryn H Schmitz, Sumanta K Pal","doi":"10.46883/2026.25921060","DOIUrl":"10.46883/2026.25921060","url":null,"abstract":"<p><strong>Background: </strong>Patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs), alone or in combination with tyrosine kinase inhibitors (TKIs), often experience significant treatment-related adverse events, including fatigue, that can impair health-related quality of life (HRQOL). Structured exercise interventions may mitigate these symptoms, but data in mRCC are limited.</p><p><strong>Objective: </strong>To evaluate the feasibility and impact of a 12-week supervised remote exercise program on HRQOL, fatigue, and symptom burden in patients with mRCC receiving ICIs or ICI-TKI combinations.</p><p><strong>Methods: </strong>Nineteen patients with mRCC (median age 67 years; 57.9% male) participated in a 12-week home-based exercise program, supervised via telehealth. The program included aerobic, resistance, and mobility exercises delivered through weekly virtual consultations and supported by the Vedius platform. Outcomes were assessed at baseline and post intervention using the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM), Brief Fatigue Inventory (BFI), and Edmonton Symptom Assessment System (ESAS).</p><p><strong>Results: </strong>Participants demonstrated significant improvements in overall HRQOL (FACT-General mean increase, 9.8 points; P  = .001; Cohen d  = 0.8), treatment-related toxicity (ICM mean increase, 10.1 points; P  = .017), and fatigue (BFI mean decrease, 21.1 points; P  = .018; ESAS fatigue mean decrease, 5.0 points; P  = .001; Cohen d  = -1.5). Symptom burden (ESAS mean decrease, 12.3; P  = .001) and key patient-reported outcomes, including anxiety, depression, appetite loss, and sleep disturbances, also improved ( P  ≤ .02).</p><p><strong>Conclusions: </strong>A 12-week supervised remote exercise program was feasible and associated with meaningful improvements in HRQOL, fatigue, and symptom burden among patients with mRCC undergoing ICI-based therapies. These findings support the integration of structured exercise into supportive care for mRCC, highlighting the potential of remote interventions to enhance physical and emotional well-being. Future studies should confirm these results in larger randomized trials and identify the most effective program components.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 1","pages":"44-47"},"PeriodicalIF":2.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}